TheraRadar
← Back
Data updated: Jun 28, 2026

HILL DERMACEUTICALS

Pharma

HILL DERMACEUTICALS is a pharmaceutical company focused on Dermatology. Key products include TOLAK.

2015
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

HILL DERMACEUTICALS's Key Drugs

HILL DERMACEUTICALS's core commercial portfolio centers on TOLAK, spanning Dermatology — its most strategically important drugs approved in the last 15 years.

HILL DERMACEUTICALS's Recent FDA Approvals

New NDA/BLA approvals for HILL DERMACEUTICALS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HILL DERMACEUTICALS's Therapeutic Areas

HILL DERMACEUTICALS's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
0 drugs Phase 1: 1

HILL DERMACEUTICALS's Top Competitors

HILL DERMACEUTICALS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

HILL DERMACEUTICALS Pipeline Snapshot

HILL DERMACEUTICALS has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • TOLAK leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling